Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …

The development of orally active small molecule inhibitors of the epidermal growth factor
receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC) …

Background The concomitant use of tyrosine kinase inhibitors (TKIs) and proton pump
inhibitors (PPIs) is a significant concern because of potential drug‐drug interaction that …

Background Proton-pump-inhibitors (PPIs) are frequently prescribed for the management of
anticancer drug-related gastrointestinal symptoms. Palbociclib is a weak base with pH …

Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …

Proton pump inhibitors (PPIs) are the most commonly used anti-acid drugs worldwide,
including among cancer patients. However, drug-drug interactions between PPIs and other …

ABSTRACT Introduction Proton pump inhibitors (PPIs) block the gastric H/K-ATPase,
therefore inhibiting acid gastric secretion, leading to an increased pH (> 4). They account for …

Background: Proton pump inhibitors (PPIs) are one of the most widely used drugs worldwide
and are overprescribed in patients with cancer; there is increasing evidence of their effects …

The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the
epidermal growth factor receptor (EGFR) has revolutionized the management of non-small …

Abstract Introduction Approximately 20–33% of all cancer patients are treated with acid-
reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce …